Cysteinyl Leukotrienes in Allergic Inflammation

The cysteinyl leukotrienes (CysLTs), LTC₄, LTD₄, and LTE₄, are potent lipid mediators derived from arachidonic acid through the 5-lipoxygenase pathway. These mediators produce both inflammation and bronchoconstriction through three distinct G protein-coupled receptors (GPCRs)-CysLT₁, CysLT₂, and OXGR1 (also known as CysLT₃ or GPR99). While CysLT-mediated functions in the effector phase of allergic inflammation and asthma have been established for some time, recent work has demonstrated novel roles for these mediators and their receptors in the induction and amplification of type 2 inflammation. Additionally, in vitro studies and murine models have uncovered diverse regulatory mechanisms that restrain or amplify CysLT receptor activation and CysLT receptor function. This review provides an overview of CysLT biosynthesis and its regulation, the molecular and functional pharmacology of CysLT receptors, and an overview of the established and emerging roles of CysLTs in asthma, aspirin-exacerbated respiratory disease, and type 2 inflammation.

airway remodeling; allergic inflammation; aspirin-exacerbated respiratory disease; asthma; cysteinyl leukotriene.